| abstract |
A Rho kinase inhibitor is provided as a novel pharmaceutical agent, particularly as a therapeutic agent of hypertension, a therapeutic agent of angina pectoris, a suppressive agent of cerebrovascular contraction, a therapeutic agent of asthma, a therapeutic agent of peripheral circulation disorder, a prophylactic agent of immature birth, a therapeutic agent of arteriosclerosis, an anti-cancer drug, an anti-inflammatory agent, an immunosuppressant, a therapeutic agent of autoimmune disease, an anti-AIDS drug, a contraceptive, a prophylactic agent of digestive tract infection, a therapeutic agent of osteoporosis, a therapeutic agent of retinopathy and a brain function improving drug, containing an amide compound of the formula: Ra-CO-NR b R c (I) in which R a is an amino(alkyl)-substituted cyclohexyl, an amino(alkyl)-substituted phenyl, pyperidyl or the like, R b is hydrogen, alkyl or the like and R c is optionally substituted N-containing heterocycle. Also disclosed a novel amide compound of the formula: (see formula III) in which L and R5 are hydrogen, alkyl or the like and Rc' is optionally substituted heterocycle other than pyridine. |